Angios is developing new treatments for challenging vascular diseases using the vascular organoid model developed by the company’s founders. The vascular organoids allow the company to model human microvascular complications in the dish and thereby find new pathways associated with disease progression. Diseases affecting blood vessel functionality remain an unresolved global health problem, especially in […]

View post to subscribe to site newsletter.

MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases. Nanobodies® are proprietary therapeutic proteins based on single-domain antibody fragments, with the benefits of conventional antibodies but at 1/10th the size. MoonLake has licensed Merck KGaA’s phase 3-ready drug sonelokimab (M1095) […]

View post to subscribe to site newsletter.

ResBiotic is developing microbiome-based products to help reduce inflammation in chronic lung diseases. The company is building on research into how the microbiota influence lung diseases, carried out by company founder and Chief Scientific Officer C. Vivek Lal at University of Alabama at Birmingham. Chronic respiratory illness is associated with lung dysbiosis (abnormal lung microbiome) […]

View post to subscribe to site newsletter.